BioSpace News Archive

MedRhythms announced today that the company’s pivotal trial for MR-001, a novel digital intervention in development to treat gait deficits in chronic stroke, was successfully completed and met its primary endpoint.

BioCentriq, Inc. announced today that they have successfully completed tech transfer of AVB-001 from client Avenge Bio and initiated manufacturing of clinical grade material, which will support Avenge Bio’s ongoing phase 1/2 clinical trial.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2022 financial results on Tuesday, February 7, 2023 after the financial markets close.

Corium Pharma Solutions, Inc. today announced the appointment of Dr. Mark Sirgo as Chief Executive Officer and member of the Board of Directors.

Tune Therapeutics , a biotechnology company pioneering the creation of genetic tuning (epigenomic editing) therapies, today announced the addition of John McHutchison AO, MD – former CEO at Assembly Biosciences, Inc., and CSO at Gilead Sciences, Inc. – to its board of directors.

Mustang Bio, Inc. today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in a fireside chat at the B. Riley Securities’ 3rd Annual Oncology Conference.

Natera Announces Publication of Prospective, Multi-Site CIRCULATE Study in Nature Medicine Demonstrating Signatera’s Ability to Predict Chemotherapy Benefit in Colorectal Cancer.

SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced additional positive pre-clinical results in ongoing series of research studies of treatment for cocaine using MEAI, a novel psychedelic molecule of Clearmind Medicine Inc.

TC Biopharm today announces a strategic collaboration with The University of Texas MD Anderson Cancer Center to expand the knowledge base of how gamma-delta T cells work in oncology settings.

SkinCure Oncology, the world leader in providing a comprehensive model for the delivery of Image-Guided Superficial Radiation Therapy (Image-Guided SRT), the most advanced non-surgical technology for the treatment of common skin cancers, today announced the availability of the technology in Massachusetts.